Cerca una sperimentazione clinica
Altra/e opzione/i di ricerca
11 Risultato/i
Sperimentazione in fase di reclutamento
= 
; Sperimentazione in corso
= 
; Sperimentazione conclusa
= 
; Finanziato da un ente associato a IRDiRC = 
; Membro di una ERN = 
Sperimentazioni cliniche nazionali
AUSTRALIA
Victoria
ADDRESS: NOT PROVIDED - AU
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) -AU
Institution: Information not provided - AU
BELGIO
ANTWERPEN
EDEGEM (ANTWERPEN)
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome - BE
Antwerp University Hospital - UZA
Dienst neurologie/Department of Neurology - UZA
CANADA
Québec
ADDRESS: NOT PROVIDED - CA
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) -CA
Institution: Information not provided - CA
FRANCIA
HAUTS-DE-FRANCE
ADDRESS: NOT PROVIDED - FR
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) -FR
Institution: Information not provided - FR
GERMANIA
Berlin
ADDRESS: NOT PROVIDED - DE
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) -DE
Institution: Information not provided - DE
ITALIA
EMILIA ROMAGNA
ADDRESS: NOT PROVIDED - IT
Studio di estensione con sostanza attiva, prospettico, a lungo termine, interventistico per valutare la sicurezza e la tollerabilità di NBI-921352 come terapia aggiuntiva in soggetti con sindrome da encefalopatia epilettica e dello sviluppo SCN8A (SCN8A-DEE)
Institution: Information not provided - IT
REGNO UNITO; GRAN BRETAGNA
Greater London
ADDRESS: NOT PROVIDED - GB
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) -GB
Institution: Information not provided - GB
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
SCN8A-DEE: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-921352 as Adjunctive Therapy in Subjects with SCN8A Developmental and Epileptic Encephalopathy Syndrome - ES
Institution: Information not provided - ES
SPAGNA
Madrid
ADDRESS: NOT PROVIDED - ES
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) -ES
Institution: Information not provided - ES
STATI UNITI
California
LA JOLLA
NEOLEV2: Efficacy of Intravenous Levetiracetam in Neonatal Seizures: A Phase 2 Randomized Blinded Controlled Study of the Efficacy of Intravenous Levetiracetam (LEV) as First Line Treatment for Neonatal Seizures - US
University of California San Diego
University of California School of Medicine
Sperimentazioni cliniche internazionali
STATI UNITI
Washington
ADDRESS: NOT PROVIDED - US